S100B protein detection in serum is a significant prognostic factor in metastatic melanoma

Oncology

Volumn 56, Issue 4, 1999, Pages 338-344

  Hauschild, Axel ^a   Engel, Gudrun ^b   Brenner, Winfried ^b   Gläser, Regine ^b   Mönig, Heiner ^b   Henze, Eberhard ^b   Christophers, Enno ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b NONE

Author keywords

Melanoma; Metastatic disease; S100B protein; Serum S100 protein; Tumor marker

Indexed keywords

PROTEIN S 100; PROTEIN S100B; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIGENS; CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROGNOSIS; S100 PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032968036     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011989     Document Type: Article

References (34)

1. Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965;19:739-744.
2. Gaynor R, Irie R, Morton D, Herschmann HR: S100 protein is present in cultured human malignant melanomas. Nature 1980;286:400-401.
3. Gaynor R, Herschmann HR, Irie R, Jones P, Morton D, Cochran A: S100 protein: A marker for human malignant melanomas? Lancet 1981;i:869-871.
4. Kligman D, Hilt DC: The S100 protein family. Trends Biochem Sci 1988;13:437-443.
5. Donato R: Perspectives in S-100 protein biology. Review article. Cell Calcium 1991;12:713-726.
6. Schäfer BW, Wicki R, Engelkamp D, Mattei M-G, Heizmann CW: Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: Rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 1995;25:638-643.
7. Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y, Ishihara K: An immunoperoxidase study of S100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol 1982;7:715-727.
8. Takahashi K, Isobe T, Ohtsuki Y, Akagi T, Sonobe H, Okuyama T: Immunohistochemical localization and distribution of S100 proteins in the human lymphoreticular system. Am J Pathol 1984;116:497-503.
9. Gatter KC, Ralfkiaer E, Skinner J, Brown D, Heryet A, Pulford KA: An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours. J Clin Pathol 1985;38:1353-1357.
10. Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ: Immunohistochemical study of melanocytic naevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 1990;66:765-771.
11. Baudier DC, Delphin C, Grunwald D, Khochbin S, Lawrence JJ: Characterisation of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc Natl Acad Sci USA 1992;89:11627-11631.
12. Persson L, Härdemark HG, Gustavsson J, Rundstrom G, Mendel-Hartwig I, Esscher T, Pahlman S: S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: Markers of cell damage in human central nervous system. Stroke 1987;18:911-918.
13. Fagnart OC, Sindic CJ, Laterre C: Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 1988;34:1387-1391.
14. Aurell A, Rosengarten LE, Wikkelsö C, Nordberg G, Haglid KG: The S-100 protein in cerebrospinal fluid: A simple ELISA method. J Neurol Sci 1989;89:157-164.
15. Guo H, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D: Clinical significance of serum S 100 in metastatic malignant melanoma. Eur J Cancer 1995;31A:924-928.
16. von Schoultz E, Hansson LO, Djureen E, Hansson J, Kärnell R, Nilsson B, Stigbrand T, Ringborg U: Prognostic value of serum analyses of S100β protein in malignant melanoma. Melanoma Res 1996;6:133-137.
17. Abraha HD, Fuller LC, Du Vivier AWP, Higgins EM, Sherwood RA: Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997;137: 381-385.
18. Henze G, Dummer R, Joller-Jemelka HI, Böni R, Burg G: Serum S100 - A marker for disease monitoring in metastatic melanoma. Dermatology 1997;194:208-212.
19. Buer S, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M, Wittke F, Hoffmann R, Ganser A, Atzpodien J: Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997;75:1373-1376.
20. Ketcham AS, Moffat FL, Balch CM: Classification and staging; in Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J (eds): Cutaneous Melanoma, ed 2. Philadelphia, Lippincott, 1992, pp 213-220.
21. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 1972;34:187-220.
22. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H: Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994;73:629-636.
23. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G: Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 1997;57:5073-5076.
24. Schaider H, Rech-Weichselbraum I, Richtig E, Seidl H, Soyer HP, Smolle J, Kerl H: Circulating adhesion molecules as prognostic factors for cutaneous melanoma. J Am Acad Dermatol 1997;36:209-213.
25. Wibe E, Hannisdal E, Paus E, Aamdal S: Neuron-specific enolase as a prognostic factor in metastastic malignant melanoma. Eur J Cancer 1992;28A:1692-1695.
26. Couvreur T, Joos G, Geerts ML, Lambert J, Naeyaert J-M: Neurone-specific enolase as serum marker in malignant melanoma. Lancet 1993;342:985-990.
27. Schutter EM, Visser JJ, van Kamp GJ, Mensdorff-Pouilly S, van Dijk W, Hilgers J, Kenemans P: The utilitiy of lipid-associated sialic acid (LASA of LSA) as serum marker for malignancy. A review of the literature. Tumour Biol 1992;13:121-132.
28. Smith B, Selby P, Southgate J, Pittmann K, Bradley C, Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-1229.
29. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Möhler T, Hunstein W: Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993;101:887-889.
30. Foss AJE, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S: The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995;72:155-159.
31. Reinhold U, Lüdtke-Hadjery H-C, Schnautz S, Kreysel H-W, Abken H: The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997;108:166-169.
32. Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M, Grimm EA: Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997;15: 2226-2831.
33. Gläser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W: Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study. J Clin Oncol 1997;15: 2818-2825.
34. Bosserhoff A-K, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, hein R, Stolz W, Buettner R: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997;57:3149-3153.